Back to Journals » Clinical and Experimental Gastroenterology » Volume 6

Therapeutic landscape for ulcerative colitis: where is the Adacolumn® system and where should it be?

Authors Vecchi M, Vernia P, Riegler G, D'Incà R, Annese V, Bagnoli S

Received 24 April 2012

Accepted for publication 27 August 2012

Published 4 January 2013 Volume 2013:6 Pages 1—7

DOI https://doi.org/10.2147/CEG.S33275

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4


Maurizio Vecchi,1 Piero Vernia,2 Gabriele Riegler,3 Renata D'Incà,4 Vito Annese,5 Siro Bagnoli5

1University of Milan, Department of Biomedical Sciences for Health, San Donato Milanese, Milan, 2Sapienza University of Rome, Department of Internal Medicine and Medical Specialties, Gastroenterology Unit, Rome, 3Second University of Naples, Gastroenterology and Endoscopy Unit, Naples, 4University of Padua, Department of Surgical and Gastroenterological Science, Gastroenterology Unit, Padua, 5University Hospital Careggi, Gastroenterology Unit, Florence, Italy

Abstract: Granulocyte-monocyte apheresis is a relatively new therapy that has been proposed, sometimes with controversial results, for the treatment of inflammatory bowel disease, particularly ulcerative colitis. The aim of the present study was to perform a thorough review of the literature on the application of this type of treatment in ulcerative colitis and discuss the results, in order to provide an opinion on its use which is shared by the involved experts. The review of the literature was performed by searching PubMed with appropriate key words. The results obtained suggest that the major role for this treatment at this moment is for those patients with steroid dependency or with major contraindications to use of steroids. However, promising, albeit very preliminary, results have also been observed in steroid-naïve subjects, and this is of particular interest in consideration of the safety profile of this therapeutic method. As such, the Adacolumn may prove useful in specific subgroups of patients. Future phenotypic, genotypic, and molecular characterization of patients with inflammatory bowel disease might prove useful in defining better those subjects who might benefit most from this treatment modality.

Keywords: ulcerative colitis, inflammatory bowel disease, guidelines, apheresis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]